Neurology billing: diagnostic components, study unit rules and infusion economics.
Neurology combines cognitively intensive office visits with technically complex diagnostics and, increasingly, high-cost infusion therapy. Each carries different risk: office visits risk under-coding, diagnostics risk component and unit errors, and infusions risk five-figure losses on a single authorisation mistake.
Key takeaways
- EEG and EMG split by component. Equipment ownership and who interprets determine global, 26 or TC billing.
- Nerve conduction studies are unit-counted. Units follow the number of nerves studied, and payers apply maximum unit edits per session.
- Infusion drugs are buy-and-bill capital. An unauthorised high-cost infusion is a direct loss, not a deferred receivable.
- Prolonged services are frequently uncaptured. Complex neurology visits often qualify but the time is never documented.
What neurology billing actually involves
Neurology practices perform diagnostics that are almost always split between a technical component, covering equipment and technician time, and a professional component, covering interpretation. Whether the practice bills globally or with modifier 26 depends entirely on who owns the equipment and where the study was performed. Since neurologists frequently read studies acquired at hospitals, the component question arises constantly, and a global bill in that situation both denies and creates recoupment exposure.
The higher-stakes area is infusion. Practices that buy biologic and immunoglobulin products carry substantial inventory cost, and reimbursement depends on correct J-code selection, accurate unit calculation and, critically, authorisation obtained before the drug is administered. A single unauthorised infusion of a high-cost agent can exceed the margin on many months of office visits.
Coding guidelines: the codes that carry the practice
| Code | Service | What supports it | Where it goes wrong |
|---|---|---|---|
95816 / 95819 / 95822 | EEG, awake and drowsy / awake and asleep / sleep only | Recording plus signed interpretation | Global billed where the facility owns the equipment |
95886 / 95885 | Needle EMG, complete / limited, per extremity | Extremity and muscles studied documented | Complete billed where a limited study was performed |
95907–95913 | Nerve conduction studies, by number of studies | Nerve count documented per session | Units exceeding the payer maximum per session |
95810 / 95811 | Polysomnography, without / with titration | Attended study meeting coverage criteria | Attended billed where home testing was required first |
96365–96368 | IV infusion, initial and additional hours | Start and stop times documented | Hierarchy applied incorrectly, losing the initial-hour rate |
99417 | Prolonged office service, each 15 minutes beyond the primary code | Total time documented past the threshold | Time not recorded, so the add-on is never billed |
ICD-10 nuances that matter here
Neurology diagnosis specificity drives both medical necessity and infusion coverage. Epilepsy should carry type and intractability where documented, since coverage for extended monitoring and newer agents keys off exactly that. Multiple sclerosis and neuropathy coding must be specific enough to support the biologic or immunoglobulin prescribed, and payer policies for those agents name qualifying diagnoses explicitly. Headache and migraine coding should reflect chronicity and refractoriness where the record supports it, because preventive therapy coverage depends on it.
Modifiers that carry the practice
- Split EEG, EMG and nerve conduction studies exactly as they split cardiology diagnostics: 26 for interpretation only, TC for equipment and technician time, global only when the same practice owns the equipment and performs the read.
- Bilateral nerve conduction studies need the correct side-specific modifiers rather than assuming a bilateral code covers both automatically, missing laterality is a common reason a legitimately bilateral study pays as if only one side was studied.
- The same error that costs cardiology practices money costs neurology practices more, because EEG and EMG equipment ownership is even less consistent across settings, verify who owns the equipment for every study read outside the office, not just the unusual ones.
NCCI edits and bundling
The E/M-plus-procedure pattern applies here too: a same-day office visit and a diagnostic study need modifier 25 on the E/M when the visit involved genuinely separate decision-making beyond ordering the test. The more neurology-specific bundling issue is between related diagnostic components, needle EMG and nerve conduction studies performed in the same session are frequently reviewed as a set, and billing both without a clear clinical rationale for each in the note invites a medical-necessity denial on one of them even when the edit itself allows both to be billed.
Medically Unlikely Edits (MUEs)
Nerve conduction studies are the specialty's clearest MUE example: units bill per nerve studied, and CMS caps the number of units payable per session based on what is clinically plausible for the presenting condition. A study that documents more nerves tested than the clinical indication supports is exactly the pattern MUE review is built to catch, which is why the nerve count in the note has to match the clinical question being answered, not a routine panel run on every patient regardless of presentation. Infusion administration codes (96365–96368) carry their own hierarchy and unit rules. The initial-hour code can only be billed once per encounter regardless of how many different drugs are infused, with subsequent hours and additional sequential infusions billed under separate add-on codes.
Medicare Fee Schedule basics
Diagnostic neurology splits its RVU profile between the technical component, which is equipment- and staff-heavy, and the professional component, which is almost entirely work RVU for the interpreting physician's time and expertise. Infusion therapy sits outside the standard E/M-driven fee schedule logic entirely: the drug itself is billed under its own J-code at a rate tied to average sales price, separate from the administration codes that pay for the clinical time delivering it, and both drift on their own update cycles, ASP rates typically update quarterly, faster than the annual MPFS conversion factor. A practice running high-cost infusions should treat drug pricing and administration pricing as two separate figures to verify, not one.
Common denials and how to resolve them
| Denial | Why it happens | Resolution | Prevention |
|---|---|---|---|
| CO-4 modifier invalid | 26 or TC wrong for equipment ownership | Rebill with the correct component | Map each study to its default component by site |
| CO-151 units exceed | Nerve conduction units above the payer maximum per session | Rebill within the limit; appeal with documentation where clinically justified | Build maximum-unit edits into the scrubber |
| CO-197 authorisation | High-cost infusion administered without authorisation | Request retro-authorisation urgently; the drug cost is otherwise at risk | Verify and document authorisation before the drug is drawn |
| CO-50 not medically necessary | Diagnosis does not meet the coverage policy for the agent or study | Appeal with clinical documentation meeting the policy criteria | Check the policy at prescribing, not at billing |
| Infusion hierarchy error | Additional-hour code billed as initial, or start/stop times missing | Rebill with correct hierarchy and documented times | Require start and stop times on every infusion record |
| CO-18 duplicate | Global and professional claims for the same study | Withdraw the duplicate | Prevent global billing where a facility claim exists |
Never let a high-cost infusion drug be drawn before the authorisation number is recorded in the chart. Unlike a denied office visit, an unauthorised biologic infusion is inventory the practice has already purchased and administered, and retro-authorisation is discretionary. One missed authorisation can erase the margin from a month of clinic.
Do and don't
- Map each diagnostic study to its component split by equipment ownership.
- Record the authorisation number before any high-cost drug is drawn.
- Document start and stop times for every infusion.
- Document total visit time so prolonged service add-ons can be captured.
- Build nerve conduction maximum-unit edits into the scrubber.
- Don't bill globally for studies performed on facility equipment.
- Don't bill a complete EMG where a limited study was performed.
- Don't administer a high-cost infusion on a verbal assurance of coverage.
- Don't exceed payer maximum units for nerve conduction studies without justification.
- Don't skip time documentation on long, complex visits.
Frequently asked questions
When do we bill modifier 26 for EEG and EMG?
Whenever the practice interprets a study performed on equipment it does not own, which is typically hospital-based work. Bill globally only when the practice owns the equipment, employs the technician and performs the interpretation. Because neurologists commonly read studies acquired at facilities, this decision recurs constantly and should be driven by the site of service in the system rather than decided per claim.
How are nerve conduction study units counted?
By the number of nerve studies performed, with the code selected according to defined ranges, and payers apply maximum allowable units per session. Exceeding the maximum denies the excess and, if it recurs, attracts review of the practice's testing patterns. Document the specific nerves studied so that the count is verifiable, and build the payer maximum into your scrubber so over-billing is caught before submission.
What protects us on high-cost infusion drugs?
A hard rule that the drug is not drawn until the authorisation number is recorded. Because the practice purchases these agents, an unauthorised administration is a realised loss rather than an unpaid claim. Additional controls that matter are correct J-code selection with accurate units, documented start and stop times, and confirming the specific product and dosing were authorised, not just the therapy in general.
Are we missing prolonged service billing?
Most neurology practices are. Complex visits routinely run past the time threshold for the prolonged service add-on, but if total time is never documented the add-on cannot be billed. The fix is a template field capturing total time on the date of service for every visit, which costs nothing clinically and makes the add-on available whenever the threshold is genuinely met.
Do you handle infusion suite billing?
Yes, including drug acquisition reconciliation, J-code and unit accuracy, administration hierarchy and authorisation tracking. For practices running an infusion suite we treat authorisation as the primary control, because it is the failure with the largest single financial consequence, and we reconcile drug purchased against drug billed so wastage and unbilled doses surface monthly.
Billing Neurology and losing revenue to denials?
We will audit a sample of your recent Neurology claims, identify the denial patterns specific to your payer mix, and show what is recoverable.